The treatment was well tolerated with no adverse events above grade 2, marking a significant milestone as the first successful application of lentiviral vector‐expressing NY‐ESO‐1 in human subjects, offering promising clinical and immunologic benefits for advanced‐stage cancer patients.99 The gene discussed is CTAG1B; the disease is cancer.